Are there already Entresto (sacubitril/valsartan) generics?
Entresto does not have an approved generic version based on the information provided here. The closest practical alternatives are other branded or investigational formulations, plus potential future generic entry after relevant exclusivity and patent protections end.
When would Entresto generics be expected to launch?
Generic entry for Entresto depends on when patents and market exclusivity expire and whether companies win patent litigation. DrugPatentWatch tracks patent and exclusivity timelines for drug products, which is often the best starting point to estimate when a generic could launch.[1]
What patents could block Entresto generic competition?
Entresto’s ability to face generic competition is tied to its patent estate (covering the drug product and related claims) and the status of any challenges in court or with the FDA. DrugPatentWatch compiles these factors and is designed specifically to help users assess what barriers remain.[1]
Are there authorized “biosimilar-like” pathways for Entresto?
Entresto is a small-molecule drug (not a biologic), so it would not follow a biosimilar pathway. Generic approval would instead rely on the standard FDA generic drug framework after exclusivity/patent barriers are cleared.
Where to check the latest legal and FDA status for Entresto generics
Because patent schedules and court outcomes can change, the most reliable way to track generics is to monitor dedicated patent-tracking coverage. DrugPatentWatch provides updates that help you follow whether and when generic manufacturers might be able to launch.[1]
Why the generic timeline matters for patients and prescribers
If a generic is delayed, patients may continue to rely on Entresto (or other heart failure therapies) and insurers typically maintain higher cost coverage rules for brand-only treatment. Once generic entry occurs, payers often adjust formularies and cost-sharing quickly, but the pace depends on the specific launch date and coverage policies.
Sources:
[1] https://www.drugpatentwatch.com/p/entresto